The SANRECO study investigates divesiran for polycythemia vera, focusing on regulating iron metabolism to control red blood cell production. Current PV treatments include therapeutic phlebotomy, ...
The current landscape of treatment for polycythemia vera is to reduce the risk of blood clotting and control blood counts. However, future treatments will need to go beyond that and target MPN stem ...
Protagonist Therapeutics, Inc. (PTGX) has been making great progress to advance the use of its drug rusfertide for the treatment of patients with polycythemia vera in the ongoing phase 3 study. Matter ...
Dr Gerds provides insight regarding the evaluation of dosing and effectiveness in PV treatment. Aaron Gerds, MD, MS: Optimal dosing of a drug, whether we’re talking interferons, hydroxide or ...
Takeda Pharmaceutical is stocking up its rare disease drug pipeline, reaching a deal for global rights to a Protagonist Therapeutics drug in late-stage development for the treatment of the rare blood ...
CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) ...
Breakthrough designation for rusfertide was supported by positive 32-week data from the Phase 3 VERIFY study, which was presented as a late breaking abstract highlighting its practice-changing ...
Q: My friend says his uncle is being treated for a disease where he has too much blood and he gets "bloodletting’" every other day, like in the Middle Ages. Is there really such a thing, or is he ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results